PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from ZERIA PHARMACEUTICAL CO.,LTD. was processed by Pulse News Wire on March 27, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

ZERIA PHARMACEUTICAL: Changes Shareholder Benefits Program Starting March 27, 2026

TOKYO, Mar 27 (Pulse News Wire) – Zeria Pharmaceutical CO.,LTD. (4559.T) announced changes to its shareholder benefits program effective March 27, 2026. The updated program introduces a new course, F

View all ZERIA PHARMACEUTICAL CO.,LTD. disclosures →

Share this disclosure: Share on X Share on LinkedIn